

Roche, GlaxoSmithKline - ALTTO trial- Tykerb alone arm discontinuation- Read-through for Head to Head Study vs. Herceptin in First line HER2+ve Breast Cancer setting

https://marketpublishers.com/r/R2EC98F58DCEN.html

Date: September 2011 Pages: 1 Price: US\$ 90.00 (Single User License) ID: R2EC98F58DCEN

Abstracts

Based on a planned interim review of early data from ALTTO (Adjuvant lapatinib and/or Trastuzumab Treatment Optimization trial), a Phase III, four arm study of adjuvant lapatinib (Tykerb), trastuzumab, their sequence and their combination in patients with HER2 positive early stage breast cancer, GSK announced that the Data Safety Monitoring Board (DSMB) has indicated that Tykerb alone arm is unlikely to meet the prespecified criteria to demonstrate non-inferiority to Herceptin alone with respect to disease free survival and hence has recommended patients assigned to Tykerb alone arm of the trial should discontinue. While DSMB has asked patients on the rest of three arms (Herceptin alone, Herceptin/Lapatinib as combination and sequential therapy) should continue on their respective therapies.



Contents

COMPANIES MENTIONED

GLAXOSMITHKLINE, ROCHE,



I would like to order

Product name: Roche, GlaxoSmithKline - ALTTO trial- Tykerb alone arm discontinuation- Read-through for Head to Head Study vs. Herceptin in First line HER2+ve Breast Cancer setting Product link: https://marketpublishers.com/r/R2EC98F58DCEN.html Price: US\$ 90.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/R2EC98F58DCEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



Roche, GlaxoSmithKline - ALTTO trial- Tykerb alone arm discontinuation- Read-through for Head to Head Study vs...